Abatacept for Gvhd Prophylaxis after Hematopoietic Cell Transplantation (HCT) for Pediatric Sickle Cell Disease (SCD): A Sickle Cell Transplant Advocacy and Research Alliance (STAR) Trial

Sonali Chaudhury(Northwestern University), Monica Bhatia(Columbia University Irving Medical Center), Allistair Abraham(Children's National), John Horan(Emory University), Hemalatha G. Rangarajan(Nationwide Children's Hospital), Gregory M.T. Guilcher(University of Calgary), Alexander Ngwube(Children's Cancer Center), Jennifer Krajewski, Ann E. Haight, Brian Volonte
Transplantation and Cellular Therapy
January 23, 2020
10.1016/j.bbmt.2019.12.085
Cited by 3

Related Papers

The genetic basis and cell of origin of mixed phenotype acute leukaemia
|Nature|2018|383
Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD
|Journal of Clinical Oncology|2021|255
Allogeneic Human Mesenchymal Stem Cell Therapy (Remestemcel-L, Prochymal) as a Rescue Agent for Severe Refractory Acute Graft-versus-Host Disease in Pediatric Patients
|Transplantation and Cellular Therapy|2013|248
Risk Factors for Acute Graft-Versus-Host Disease After Human Leukocyte Antigen–Identical Sibling Transplants for Adults With Leukemia
|Journal of Clinical Oncology|2008|204
Unrelated Donor Cord Blood Transplantation for Children with Severe Sickle Cell Disease: Results of One Cohort from the Phase II Study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN)
|Transplantation and Cellular Therapy|2012|201